AQUIOS CL Flow Cytometer Accepted by WHO Prequalification of In Vitro Diagnostics Programme

Fast, Compact, Fully Automated Instrument for CD4 Monitoring

 

The AQUIOS  CL flow cytometer has been accepted by the World Health Organization (WHO) Prequalification of In Vitro Diagnostics Program.  It can be used specifically for the immunologic assessment of patients having, or suspected of having, immune deficiency.

 

FLOWC-HIV AQUIOS In use - Section Seven

 

 

The World Health Organization (WHO) Prequalification of In Vitro Diagnostics (IVDs) Programme aims to promote and facilitate access to safe, appropriate and affordable in vitro diagnostics of good quality in an equitable manner. Focus is placed on in vitro diagnostics for priority diseases and their suitability for use in resource-limited settings.

 

The Prequalification IVD Programme has accepted the AQUIOS  CL cytometer together with the AQUIOS  Tetra1 Panel (CD45FITC/CD4RD1/CD8 ECD/CD3PC5) and AQUIOS  ImmunoTrol/ImmunoTrol low controls.  They are intended for use with invitro diagnostic flow cytometric applications, involving four fluorescent detection channels using a blue (488 nm) laser, two light scatter detection channels and electronic volume (EV).**

 

 

“Beckman Coulter is committed to developing HIV monitoring

solutions that contribute directly to the treatment process,”

explained Mario Koksch PhD, Vice President of the Cytometry

Unit for Beckman Coulter Life Sciences. 

 

 

The company’s CARES Global Health Initiative is designed to provide innovative solutions for the monitoring of HIV and AIDS treatment.  It started in 2004 after Professor Debbie Glencross, a South African laboratory pathologist, found a different and less expensive way to measure a patient’s CD4 count. The development of this compact, fully automated instrument to run that assay and carry out the accurate characterization of T cell CD4 subsets is the latest part of this initiative.


The AQUIOS  is the first authentic ‘LOAD & GO’ cytometry system and designed specifically to streamline workflow and reduce backlogs when handling applications, such as immunophenotyping.  It is suitable for clinical labs of all sizes and requires minimal training to operate.

 

Explaining the benefits of the compact instrument for use in resource-limited labs, Dr Koksch added:

 

“The small footprint, high-throughput AQUIOS  helps improve workflow in all sizes of labs,

even those with limited access to highly trained staff.  In addition, its cap piercing technology

provides additional safety for staff reducing their need to handle open blood tubes and risk exposure to biohazardous material.”

 

**These reagents provide identification and enumeration of the following lymphocyte subset populations:

·total CD3+, CD3+CD4+,CD3+CD8+, CD3+CD4+/CD3+CD8+ (ratio only) lymphocyte percentages and absolute counts;
·CD45+ absolute count; and
·CD45+ Low SS (lymphocytes) percentage and absolute count.

Read Workflow Comparison of

Study with AQUIOS CL FLOW

Cytometer

FLOWC_HIV CD4 London health Sciences AQUIOS - Section 7

Contact Us


















Please keep me informed about Beckman Coulter webinars, products, goods, and services, including products, goods, or services from our related companies.



By submitting this form I confirm that I have reviewed and agree with the Privacy Policy and Terms of Use. I also understand my privacy choices as they pertain to my personal data as provided in the Privacy Policy under “Your Privacy Choices”.

Innovation In CD4 Testing

HIV Advanced Disease Management ​

More than a third of people starting ART have advanced HIV disease, and an increasing number of patients re-present to care at an advanced stage of HIV disease following disengagement from care. The leading causes of morbidity and mortality in these patients include tuberculosis, severe bacterial infections, cryptococcal meningitis, toxoplasmosis, and Pneumocystis jirovecii pneumonia.

HIV Diagnosis Becomes up to Four Times Faster Thanks to This Invention

HIV/AIDS Africa’s poorest and most vulnerable can benefit from simple HIV test which monitors disease progression, enabling governments to deliver comprehensive treatment programs.

AQUIOS CL Flow Cytometer Accepted by WHO Prequalification of In Vitro Diagnostics Programme

The AQUIOS  CL flow cytometer has been accepted by the World Health Organization (WHO) Prequalification of In Vitro Diagnostics Program. 

Case Study: London Health Sciences Centre (LHSC)

The flow cytometry laboratory at Victoria Hospital is situated within a tertiary care academic institution, London Health Sciences Centre.